US court rules against sanofi-aventis on Lovenox patent

sanofi-aventis announced that the US District Court for the Central District of California has ruled against sanofi-aventis in its patent infringement suit against Amphastar and Teva. sanofi-aventis is currently evaluating its options for further legal recourse and will continue to vigorously defend its intellectual property rights, a company release stated. . While several companies have requested marketing approval from the FDA for their products alleged to be generic versions of Lovenox, sanofi-aventis has not learned to date of any FDA approval of these requests, the release added.